Fremanezumab (AJOVY®) receives positive recommendation by NICE for chronic migraine

Written by Sharon Salt, Senior Editor

Teva Pharmaceutical Europe BV (Tel Aviv, Israel) has announced that NICE has recommended fremanezumab (AJOVY®) for the treatment of chronic migraine in adults. This recommendation is aimed towards individuals with chronic migraine who have not responded to at least three prior preventive drug treatments.

Fremanezumab is a long-acting treatment indicated for the prophylaxis of migraine in adults who have at least four migraine days per month. It is available as a 225 mg/1.5 ml single dose injection in a pre-filled syringe with two dosing options available – 225 mg monthly administration as one subcutaneous injection, or 675 mg every 3 months administered subcutaneously.

Fremanezumab is one of several monoclonal antibodies that are specifically designed to target the CGRP pathway, which is known to be a key contributor to migraine. In September 2018, the drug was approved by the US FDA for the preventive treatment of migraine in adults.

You might also like:

“NICE’s decision to approve the use of AJOVY® [fremanezumab] on the NHS in England and Wales for patients with chronic migraine is fantastic news,” commented Mark Weatherall, President of the British Association for the Study of Headache.

“Anyone who looks after people with chronic migraine understands just how debilitating this neurological disorder can be. We have waited a long time for this new class of drug to be made available in the NHS, but now that we can prescribe fremanezumab, I am excited to see what a difference it will make to the lives of many of my worst affected patients,” he added.

This decision was based on a dossier submitted to NICE for a Single Technology Appraisal. Following issuance of the Final Appraisal Document, NICE will provide its formal guidance to the NHS in England.